drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (autologous BCMA-directed CAR-T cells)
drug_description
An autologous BCMA-directed chimeric antigen receptor T-cell (CAR-T) therapy in which a patient's T cells are gene-modified to express a CAR targeting BCMA, leading to T-cell activation, cytokine release, expansion, and targeted cytotoxic killing of malignant plasma cells in multiple myeloma.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are genetically engineered to express a chimeric antigen receptor targeting BCMA on malignant plasma cells; antigen engagement activates the T cells, inducing cytokine release, clonal expansion, and targeted cytotoxic killing of multiple myeloma cells.
drug_name
SENL103
nct_id_drug_ref
NCT06067581